Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Nine-weeks Administration of Three Doses of SB-683699 in Subjects With Moderately to Severely Active Crohn's Disease A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and ...